Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.37 |
| ▸ | GABRD | O14764 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8039855 | 0.77 | MEN1 (1.00) | MAPTMEN1KMT2AGAATDP1 | |
| SCHEMBL20125060 | 0.77 | MAPT (0.66) | MAPTMEN1KMT2AGAATDP1 | |
| SCHEMBL11540656 | 0.74 | MAOA (0.57) | MAPTMEN1KMT2AGAATDP1 | |
| SCHEMBL4777597 | 0.74 | GPR35 (0.60) | MAPTMEN1KMT2AGAATDP1 | |
| SCHEMBL6176327 | 0.73 | MAPT (0.65) | MAPTMEN1KMT2AGAATDP1 | |
| SCHEMBL3072829 | 0.73 | MAPT (0.60) | MAPTMEN1KMT2AGAATDP1 | |
| SCHEMBL15828669 | 0.73 | MEN1 (0.60) | MAPTMEN1KMT2AGAATDP1 | |
| SCHEMBL25404731 | 0.73 | CYP2A6 (0.52) | MAPTCYP2A6ALDH1A1LMNAMAOA | |
| SCHEMBL8440411 | 0.73 | CYP2A6 (0.52) | MAPTMEN1KMT2ATDP1CYP2A6 | |
| SCHEMBL16686379 | 0.73 | CYP2A6 (0.52) | MAPTMEN1KMT2ACYP2A6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795255-B2 | Rigidified compounds for modulating heparanase activity | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2010-09-14 | — | — | US | disclosed |
| US-20080039456-A1 | Rigidified Compounds for Modulating Heparanase Activity | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2008-02-14 | — | — | US | disclosed |
| EP-1846383-A2 | RIGIDIFIED COMPOUNDS FOR MODULATING HEPARANASE ACTIVITY | Insight Biopharmaceuticals Ltd. (IL) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006072953-A2 | RIGIDIFIED COMPOUNDS FOR MODULATING HEPARANASE ACTIVITY | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2006-07-13 | — | — | WO | disclosed |
| US-4680292-A | Carbapenems and 1-methylcarbapenems having a 2-heteroaryliumaliphatic substituent | MERCK & CO., INC. (US) | 1987-07-14 | — | — | US | disclosed |
| EP-0160876-A1 | 1-Hetero-6-/1-Hydroxyethyl/-2-SR8-1-carbadethiapen-2-EM-3-carboxylic acids | MERCK & CO. INC. (US) | 1985-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039456-A1 | Rigidified Compounds for Modulating Heparanase Activity | HPSE, HEXA, GAA | MAPT 2880/4885MEN1 3219/4885KMT2A 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.